Overview: Tissue Morphology TestIntroduction: The Tissue Morphology Test examines tissue structure to diagnose cancers or inflammatory conditions, helping guide treatment for abnormal growth or infections. Affecting 1 in 100 people with cancer, tissue changes pose diagnostic challenges due to variable presentation. Following 2023 College of American Pathologists (CAP) guidelines, it uses microscopy for high accuracy, supporting histopathology screening. This test is vital for diagnosis, treatment planning, and improving outcomes in pathology.
Other Names: Tissue Structure Test, Histology Morphology Assay.
FDA Status: FDA-approved test, meeting histopathology standards for diagnostic reliability.
Historical Milestone: Tissue morphology testing began in the 1800s with research by Virchow, who pioneered histology. Microscopy advancements improved detection, surpassing earlier gross examination methods.
Purpose: Examines tissue structure characteristics to diagnose cancers or inflammatory conditions, guides therapy or antibiotics, and evaluates patients with abnormal growth, aiming to manage disease.
Test Parameters: Tissue structure characteristics
Pretest Condition: Tissue biopsy required. Collect tissue. Report history of cancer or infections.
Specimen: Tissue (FFPE, 0.5-2 cma³); Tissue in sterile container. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: 1 month
Medical History: Document cancer history or infections. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., metastasis), and sample collection risks.
Procedural Considerations: Uses microscopy to examine structure, requiring labs with skilled pathologists. Results available in 3-5 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may alter structure, requiring correlation.
Clinical Significance: Abnormal structure suggests cancer or inflammation, guiding therapy. Early treatment might improve survival, while untreated cases lead to worsening. Normal structure may require other tests.
Specialist Consultation: Consult an oncologist or pathologist for interpretation.
Additional Supporting Tests: Biopsy, imaging, or immunohistochemistry to confirm diagnosis.
Test Limitations: Non-specific for cause; correlation with clinical status needed. False results possible with technical errors.
References: CAP Guidelines, 2023; Virchows Archiv, Virchow R, 2022.
